Drug Approval | February 01, 2024
Orchid Pharma's Exblifeb granted EMA approval
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
About 75% of all primary liver cancers in adults are HCC and up to 30% of HCC patients are eligible for embolisation
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Union Ayush Minister with Assam Chief Minister lays foundation stone for Central Research Institute of Yoga & Naturopathy
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
Gabapentin is indicated for the management of Postherpetic Neuraligia
The registered capital of the newly founded company is € 50 million
Subscribe To Our Newsletter & Stay Updated
